Shanghai Junshi Biosciences Co., Ltd.
Other OTCTotal Valuation
Shanghai Junshi Biosciences Co., Ltd. carries a market capitalization of 4.84B, placing it among publicly traded companies globally. Its enterprise value stands at -615.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.84B |
| Enterprise Value | -615.40M |
Share Statistics
Shanghai Junshi Biosciences Co., Ltd. currently has 984.87M shares outstanding.
| Shares Outstanding | 984.87M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 103.31 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 20.96 |
Financial Position
Shanghai Junshi Biosciences Co., Ltd. maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.79, indicating elevated leverage, while an interest coverage ratio of -41.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.07 |
| Quick Ratio | 1.42 |
| Debt / Equity | 38.79 |
| Debt / EBITDA | -2.56 |
| Interest Coverage | -41.20 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -9.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.35 |
Taxes
| Income Tax | 1.66M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Shanghai Junshi Biosciences Co., Ltd.'s stock has gained approximately 70.05076% over the past 52 weeks. The 50-day moving average sits at 3.13, while the 200-day moving average is 3.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | 70.05076% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 3.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Junshi Biosciences Co., Ltd. generated 116.35M in revenue and converted that into -1.06B in net income, yielding earnings per share of -1.15. EBITDA reached -1.01B, while operating income came in at -1.01B.
| Revenue | 116.35M |
| Gross Profit | 575.26M |
| Operating Income | -1.01B |
| Pretax Income | -1.12B |
| Net Income | -1.06B |
| EBITDA | -1.01B |
| EBIT | -1.01B |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
Shanghai Junshi Biosciences Co., Ltd. holds 3.31B in cash and equivalents against 2.57B in total debt, resulting in a net debt position of -170.94M. Total book value stands at -8.70B, with working capital of 2.49B providing operational flexibility.
| Cash & Cash Equivalents | 3.31B |
| Total Debt | 2.57B |
| Net Debt | -170.94M |
| Equity (Book Value) | -8.70B |
| Book Value Per Share | -8.92 |
| Working Capital | 2.49B |
Cash Flow
After subtracting -796.93M in capital expenditures, free cash flow totaled -796.93M - equivalent to -0.82 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -796.93M |
| Free Cash Flow | -796.93M |
| FCF Per Share | -0.82 |
Margins
Shanghai Junshi Biosciences Co., Ltd. operates with a gross margin of -81.17, reflecting its pricing power and cost economics. The operating margin of -863.84 and net profit margin of -907.66 provide insight into operational efficiency.
| Gross Margin | -81.17 |
| Operating Margin | -863.84 |
| Pretax Margin | -959.65 |
| Profit Margin | -907.66 |
| EBITDA Margin | -863.84 |
Dividends & Yields
The company's payout ratio of -1.16 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | -1.16 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
Shanghai Junshi Biosciences Co., Ltd. posts an Altman Z-Score of -1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.27 |